Inside the research

Abbott Laboratories

ABT Research profile · latest available data

Price overview

$101.29

▲ +0.22 (+0.2%)

52w hi$131.55
52w lo$81.98
Vol7.78M
As of25 Sep 2026

The Verdict

Hold

Our score +0.09

Short+0.06
Medium+0.18
Long-0.03

computed 2026-09-27

Key fundamentals

Abbott Laboratories

Healthcare · Medical Devices

Market cap$175.27B
Enterprise value$203.04B
Trailing P/E32.78x
Forward P/E16.70x
EV / EBITDA17.38x
P / S (ttm)3.79x
Profit margin11.6%
Return on equity10.6%
Revenue growth+13.0%
Earnings growth-47.5%
Debt / equity63.21

Layer Breakdown

LayerRawContribution
Fundamental+0.11
Sector+0.08
Technical+0.05
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

United States · www.abbott.com

Risk Metrics

Beta vs SPX0.19
Corr SPX0.12
Annual vol24.5%
Annual ret-2.8%
Sharpe-0.11
Max DD-41.1%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$118.64
High / Low$143.00 / $92.00
Median$120.00
Analysts25
Strong Buy5
Buy16
Hold7
Sell0
Strong Sell0

Recent rating actions

2026-04-27BTIG→ Buy
2026-04-20Barclays→ Overweight
2026-04-17Stifel→ Buy
2026-04-17RBC Capital→ Outperform
2026-04-17Piper Sandler→ Overweight
2026-04-17Oppenheimer→ Outperform

Officers & Board

DirectorMichael G. O'Grady since 2023
DirectorClaire Babineaux-Fontenot since 2022
DirectorPaola Gonzalez since 2021
DirectorMike Roman since 2021
CEORobert B. Ford since 2020
DirectorDarren W. McDew since 2019
DirectorRobert B. Ford since 2019
DirectorMichelle Kumbier since 2018
DirectorJohn Stratton since 2017
DirectorDaniel Starks since 2017
DirectorSally Blount since 2011
DirectorNancy McKinstry since 2011
DirectorRobert Alpern since 2008
ManagerRobert B. Ford current
ManagerMiles D. White current

Material Events

DateEvent8-K
2026-07-16Earnings Release, Exhibitsread
2026-04-27Officer / Director Change, Bylaws Amendment…read
2026-04-17Other Material Event, Exhibitsread
2026-04-16Earnings Release, Exhibitsread
2026-03-23Other Material Event, Exhibitsread
2026-03-09Material Agreement, Material Obligation…read
2026-02-26Material Agreement, Exhibitsread
2026-02-20Bylaws Amendment, Exhibitsread
2026-01-22Earnings Release, Exhibitsread
2025-12-12Officer / Director Change, Bylaws Amendment…read
2025-11-215.04, Exhibitsread
2025-11-20Material Agreement, Reg FD Disclosure…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-12Morrone Louis H.Officer, EXECUTIVE VICE PI12$1.30K
2026-08-11Morrone Louis H.Officer, EXECUTIVE VICE PSell5.85K$642.51K
2026-06-30Morrone Louis H.Officer, EXECUTIVE VICE PWithheld for tax269$24.94K
2026-06-27Cushman Elizabeth C.Officer, EVP, GC AND SECRWithheld for tax560$52.71K
2026-05-07Stratton John GDirectorBuy2.00K$173.64K
2026-04-28Moreland Mary KOfficer, EXECUTIVE VICE PI5.31K$501.69K
2026-04-27STARKS DANIEL JDirectorBuy10.00K$926.54K
2026-04-24O'Grady MichaelDirectorGrant2.29K—
2026-04-24Roman Michael FDirectorGrant2.29K—
2026-04-24Stratton John GDirectorGrant2.29K—

Flow & Concentration

Insider 180d net$658.97K
Insider buys / sells3 / 1
Insider biasNeutral
13F holders9
Top-5 share96.1%
HHI4,394 (concentrated)

Top Holders

HolderValueShares
State Street Corp$7.34B80.93M
Fidelity / FMR LLC$1.22B13.42M
Citadel Advisors$1.09B12.07M
Capital Research / Capital World$967.52M10.66M
Millennium Management$399.75M4.41M
AQR Capital Management$380.48M4.19M
Renaissance Technologies$62.28M686.37K
Bridgewater Associates$5.42M59.77K
T. Rowe Price Group$2.07M22.79M

As of 2026-06-30

Dividends

Yield (TTM)1.83%
$ / share (TTM)$1.85
5y CAGR+10.4%

Annual dividend per share

2021$1.80
2022$1.88
2023$2.04
2024$2.20
2025$2.36
2026$1.26

Federal Contracts

AmountAgencyDescription
$65.47MDepartment of Health and Human ServicesABBOTT: TO CONDUCT CLINICAL TRAINING AND VALIDATION STUDIES TO SUPPORT A FUTURE
$37.60MDepartment of DefenseLABORATORY ASSAY FOR TRAUMATIC BRAIN INJURY
$12.12MDepartment of Veterans AffairsIGF::OT::IGF CHEMISTRY ANALYZERS/AUTOMATION COST-PER-REPORTABLE RHJ VAMC CHARLES
$11.36MDepartment of Veterans AffairsVISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE
$10.11MDepartment of Veterans AffairsCHEMICAL ANALYZER
$9.42MDepartment of Veterans AffairsLAB CHEMISTRY SERVICES
$7.09MDepartment of Veterans AffairsVISN 15 CHEMISTRY BPA
$6.70MDepartment of DefenseCHEMISTRY/IMMUNOASSAY

SEC Filings

DateFormDoc
2026-08-134view
2026-07-2810-Qview
2026-07-168-Kview
2026-07-014view
2026-07-014view
2026-07-014view
2026-07-014view
2026-07-014view
2026-07-014view
2026-06-294view
2026-06-184view
2026-06-1811-Kview
2026-04-294view
2026-04-2910-Qview
2026-04-284view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$41.95B+3.1%
Gross profit$4.40B-3.3%
Operating income$6.48B+0.2%
Net income$6.52B+14.8%
Cash from ops$7.26B-2.1%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$100.81$101.82$100.09$101.297.78M
Sep 24$103.77$104.22$101.02$101.076.22M
Sep 23$104.22$104.31$102.66$103.4912.18M
Sep 22$104.01$104.54$102.90$103.698.38M
Sep 21$102.27$103.20$101.84$102.985.02M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →